For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Joe Biden wants diabetes drugs that aid weight loss and treat obesity, such as Wegovy, to fall under Medicare and Medicaid.

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

A recent groundbreaking study found that Glucagon-like peptide 1 receptor agonists (GLP1-RA) are effective in reducing venous ...